Switching to alemtuzumab from subcutaneous interferon beta-1a after CARE-MS I further improved MRI outcomes in patients with relapsing-remitting multiple sclerosis

Authors
Category Primary study
JournalNeurology
Year 2015
This article has no abstract
Epistemonikos ID: f85af84baa4e5da326a2d089c136675d33a385b0
First added on: Apr 30, 2026